Darlifarnib combined with cabozantinib in advanced RCC showed objective response rates of 33%-50% and a median PFS of 13 months, with a manageable safety profile. The ongoing phase I-B expansion is randomizing against cabozantinib monotherapy, supporting further development in later-line RCC and po…
Darlifarnib combined with cabozantinib in advanced RCC showed objective response rates of 33%-50% and a median PFS of 13 months, with a manageable safety profile. The ongoing phase I-B expansion is randomizing against cabozantinib monotherapy, supporting further development in later-line RCC and potential broader combinations.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
